Company news
Korro Bio, Inc. (NASDAQ:KRRO) news
Korro Bio, Inc. news releases on 6ix. Latest, Oct 5, 2026: Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121
Press releases & updates
Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121
October 5, 2026
Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121
October 4, 2026
Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 6, 2026
Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 10, 2026
Korro to Present at the 2026 Jefferies Global Healthcare Conference
May 26, 2026
Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency
May 20, 2026
Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
May 18, 2026
Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 7, 2026
Korro Announces Oral and Poster Presentations at Upcoming Scientific Conferences
April 16, 2026
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 10, 2026
Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 12, 2026
Korro Announces Oversubscribed $85 Million Private Placement
March 9, 2026
Korro to Present at the TD Cowen 46th Annual Health Care Conference
February 25, 2026
Korro to Host Virtual Analyst Day on January 27, 2026
January 20, 2026
Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 8, 2026
Korro Reports Third Quarter Financial Results, Provides Updates on KRRO-110 in Alpha-1 Antitrypsin Deficiency and Additional Pipeline Programs
November 12, 2025
Korro to Participate in Upcoming Investor and Scientific Conferences
September 2, 2025
Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates
August 12, 2025
Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110
July 21, 2025
Korro to Participate in Upcoming Investor Conferences
May 14, 2025
Korro Reports First Quarter 2025 Financial Results and Provides Business Updates
May 7, 2025
Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer
April 1, 2025
Korro Reports Full Year 2024 Financial Results and Provides Business Updates
March 18, 2025
KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency
March 14, 2025
Korro to Present at the TD Cowen 45th Annual Health Care Conference
February 26, 2025
Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency and Provides Pipeline Update
January 12, 2025
Korro to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 6, 2025
Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency
November 20, 2024
Korro to Present at the Jefferies London Healthcare Conference
November 13, 2024
Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 11, 2024
Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board
November 3, 2024
Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society
September 29, 2024
Korro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates
September 15, 2024
Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors
August 27, 2024
Korro to Participate in Upcoming September Investor and Scientific Conferences
August 26, 2024
Korro Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 12, 2024
Korro Joins the Russell 2000®, Russell 3000®, and Russell Microcap® Indexes
June 30, 2024
Korro to Participate in Upcoming June Investor and Scientific Conferences
May 29, 2024
Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference
May 19, 2024
Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer
May 13, 2024
Korro Announces $70 Million Private Placement
April 17, 2024
Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress
March 25, 2024
Korro to Present at the TD Cowen 44th Annual Health Care Conference
February 26, 2024
Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio
January 17, 2024
Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 3, 2024
Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
December 6, 2023
Korro Bio Appoints Dr. Rachel Meyers to Board of Directors
November 27, 2023
Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results
August 9, 2023
Korro Bio and Frequency Therapeutics Announce Merger Agreement
July 13, 2023
Frequency Therapeutics Provides Business Updates and First Quarter 2023 Financial Results
May 11, 2023